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The focus for HPV genotyping has largely been on types 16 and 18, based on their high prevalence in cervix cancer. However screening is focussed on the
detection of high grade precursor lesions (CIN3 and CIN2), where other types have a greater role. While HPV16 retains its high predictive value in this
context, HPV31 and especially HPV33 emerge as important types with higher positive predictive values (PPVs) than HPV18. Additionally full typing
indicates that types 39, 56, 59 and 68 have much lower PPVs than types 16, 18, 31, 33, 35, 45, 51, 52 and 58 and they should be considered as ‘intermediate
risk’ types, whereas type 66 should not be treated as having an increased risk. Available data are summarized to support this view.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The ATHENA (Addressing The Need for Advanced HPV Diag-
nostics) trial was a very large registration trial for the use of Ro-
che's Cobas human papillomavirus (HPV) test in primary cervical
screening and for the triage of atypical squamous cells of unknown
signiﬁcance (ASC-US). Over 42,000 women aged 25y or older were
enrolled. The study has provided convincing evidence that HPV
testing alone as the primary screening modality is more sensitive
than cervical cytology at all ages and is as sensitive as HPV co-
testing with cytology in women aged 30y and over [1]. As a result
of this study, Cobas is now licenced by the Food and Drug Ad-
ministration (FDA) in the United States for primary screening in
women aged 25y and older and for ASC-US triage in women aged
21y and older. The Cobas test is based on polymerase chain reac-
tion (PCR) ampliﬁcation of HPV DNA using liquid-based cervical
cytology samples and detects HPV 16 and 18 separately with a
consensus pool for 12 other high-risk HPV types. This trial has
conﬁrmed that positivity for HPV 16 carries a higher risk than a
pool of other high risk types for the detection of high grade cer-
vical intraepithelial neoplasia (CIN) [2]. However based on data
from this trial, Monsonego et al. [3] have suggested that typing
only for HPV types 16 and 18 is all that is needed to assess the risk
of high-grade cervical intraepithelial neoplasia (CIN grade 2 (CIN2)
or CIN grade 3 (CIN3)) in a screening context. While important,
this is a gross oversimpliﬁcation based on currently available data,
where further discrimination of risk based on extended HPV typ-
ing is clearly apparent.
Firstly, while much less common than HPV 16, HPV 33 has si-
milar predictive power for detection of high-grade CIN (CIN2 and
CIN3) and HPV 33 also carries a high risk for invasive cervical
cancer. This is seen in a number of other large studies assessing
HPV genotype-speciﬁc cervical disease risks (Tables 1 and 2). HPV
33 has a higher positive predictive value for CIN2þ and CIN3þ
than HPV 18, for all studies, except in a study conducted in Kaiser
Permanente Northern California (KPNC) where the risk wasx.doi.org/10.1016/j.pvr.2016.05.004
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higher risk than other ‘high risk HPV types’ and has a higher risk
than HPV 18 for most of the studies shown in Table 1. For squa-
mous cancers, HPV 16 is clearly dominant and HPV 18 fares
somewhat better, typically ranking second in relative risk
(Table 2B). HPV 45 also emerges in the top four HPV genotypes
causing invasive cervical cancer, but it ranks lower for high-grade
precursor lesions. This type has been combined with HPV18 in
some assays (notably Hologic Aptima). Only for adenocarcinoma
(including adenosquamous cancer) does HPV 18 carry the highest
relative risk (Table 2B). Data on full HPV typing is quite sparse for
adenocarcinoma in situ (AIS), but again in the available data HPV
18 carries the highest relative risk.
Another large international study of cancer with full genotyp-
ing was reported by Sanjose et al. [24] involving 10,575 cases. No
control data were given in that study, but a contemporary study of
negative cytology was reported by many of the same authors [25].
There were not enough data to compute conﬁdence intervals but
the rankings for squamous cancer would be 16, 45, 33,18 and 31,
whereas for adenocarcinoma they would be 45, 18, 16, 33, 31.
Secondly, other individual HPV genotypes within commonly
grouped categories of “other” high-risk HPV genotypes do not
carry equal risk [4], and some – notably HPV 39, 56, 59, 66 and 68
would be better considered as ‘intermediate risk’ and potentially
have less active clinical management than other high-risk HPV
genotypes, e.g., if cytology negative repeat screening at 2–3 years
rather than after one year. Further analyses and new data indicate
that type 66 carries little or no risk, and should be dropped alto-
gether from the group of ‘increased risk’ HPV types [5,6]. The In-
ternational Agency for Research on Cancer (IARC) dropped its as-
sessment of sufﬁcient evidence for carcinogenicity for HPV66 in
2009 [7].
Lastly, there is little discrimination between types 16 and 18 in
the report of Monsonego et al. [3], whereas again numerousC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Prevalence of HPV 16, 18, 31, 33 and positive predictive value (PPV) or relative risk (RR, where indicated) for CIN2þ and CIN3þ in different studies.
Study [ref] HPV type Population CIN2þ CIN3þ
prevalence % (95% CI)
PPV (95% CI) rank PPV (95% CI) rank
ATHENA (N¼40 901) [[3], (Table 3)] 16 2.1 (1.9, 2.2) 19.5 (16.8, 22.3) 1 14.7(12.2, 17.3) 1
18 .82 (.73, .91) 8.4 (5.64, 11.9) 4 6.9 (4.4, 10.2) 4
31 1.0 (.92, 1.1) 15.2 (11.9, 19.0) 2 8.0 (5.5, 11.0) 2
33 .28 (.23, .33) 9.7 (4.96, 16.8) 3 7.1 (3.1, 13.5) 3
NMHPVPR (N¼47 617, 3y FU) [[13], Table 1; [14], Table 3]] 16 3.5 (3.3, 3.6) 10.9 (6.1, 12.7) 1.5 8.0 (6.5, 9.6) 1
18 1.2 (1.1, 1.3) 5.7 (3.4, 7.9) 4 2.9 (1.5, 4.3) 4
31 1.8 (1.7, 1.9) 7.3 (4.7, 9.9) 3 3.1 (1.9, 4.4) 3
33 .50 (.43, .57) 10.9 (5.8, 16.0) 1.5 5.2 (1.8, 8.6) 2
FUTURE I (N¼1694, 3y FU) [[15], Table 1] 16 13.9 (12.4, 15.5) 9.2 (6.0, 13.2) 2 1.7 (0.0, 3.8) 3
18 5.8 (4.8, 6.9) 4.4 (1.4, 10.0) 4 0 (-) –
31 8.0 (6.8, 9.3) 8.9 (5.0, 14.5) 3 3.2 (0.0, 8.8) 2
33 2.9 (2.2, 3.7) 14.0 (6.26, 25.8) 1 4.1 (0.0, 10.5) 1
KPNC (3y FU) (N¼18 810, HPVþ , cyto neg, 430y) [[6], Tables 2 and 3)] 16 14.7 (14.2, 15.2) 16.7 (15.5, 17.9) 1 10.6 (.89, 11.4) 1
18 6.3 (6.0, 6.7) 9.4 (8.3, 10.7) 4 5.9 (5.2, 6.7) 2
31 10.1 (9.7, 10.5) 10.2 (9.3, 11.3) 3 4.5 (4.1, 5.0) 4
33 2.2 (2.0, 2.4) 8.9 (7.1, 11.0) 6 5.9 (4.8, 7.2) 3
HPV 52-2nd; HPV35-5th
Predictors 2 (referral) N¼1067 [[4], Table 3 and new dataa] 16 30.2 (27.4, 33.0) 57.8 (52.2, 63.2) 2 42.3 (37.0, 47.8) 1
18 5.4 (4.1, 7.0) 29.3 (18.1, 42.8) 4 15.2 (6.34, 28.9) 6
31 7.6 (6.1, 9.4) 39.5 (28.8, 51.0) 3 22.2 (13.7, 32.8) 3
33 7.7 (6.2, 9.4) 59.8 (48.3, 70.4) 1 31.0 (20.5, 43.1) 2
HPV35-4th; HPV52-5th
New Mexico [[16], Table 2 and new data for CIS onlya] (RR) N¼5020 16 7.4 (6.6, 8.3) 5.8 (5.2, 6.3) 1
18 2.3 (1.8, 2.8) 1.8 (1.5, 2.2) 4
31 2.9 (2.4, 3.5) 2.7 (2.4, 3.1) 3
33 .92 (.65, 1.3) 3.4 (3.0, 3.8) 2
Sweden 14y risk (N¼11 685) [[17], Tables 1, 2 and 4] 16 2.4 (2.18, 2.74) 42.8 (36.4, 49.8) 2 34.5 (28.4, 41.5) 1
18 .62 (.49, .79) 39.4 (28.4, 52.8) 4 29.7 (19.6, 43.4) 3
31 1.0 (.84, 1.22) 41.9 (31.1, 54.6) 3 28.4 (18.2, 42.7) 4
33 .38 (.27, .51) 54.2 (37.6, 72.5) 1 34.1 (19.2, 55.6) 2
Controls in Vaccine trials (15–26y) (N¼17 590) [[18], Tables 1 and 3] 16 8.8 (8.4, 9.3) 26.3 (24.1, 28.6) 1 15.5 (13.7, 17.4) 1
18 3.6 (3.4, 3.9) 12.5 (10.0, 15.3) 4 5.6 (4.0, 7.7) 4
31 4.4 (4.1, 4.8) 18.3 (15.7, 21.2) 3 8.6 (6.7, 10.8) 3
33 2.0 (1.8, 2.2) 23.5 (19.2, 28.2) 2 13.4 (10.1, 17.4) 2
POBASCAM Baseline- (N¼44 102) [19, Tables 1 and 2] 16 1.6 (1.5, 1.8) 20.8 (17.9, 24.0) 1 17.1 (14.4, 20.0) 1
18 .42 (.37, .49) 7.4 (4.1, 12.3) 3 5.3 (2.6, 9.6) 3
31 .64 (.57, .72) 7.1 (4.4, 10.8) 4 5.0 (2.8, 8.2) 4
33 .27 (.22, .32) 14.4 (8.6, 22.1) 2 12.7 (7.3, 20.1) 2
Denmark [[20], Tables 1 and 2] (N¼40 382) 16 5.4 (5.1, 5.9) 15.7 (14.1, 17.3) 1 13.2 (11.8, 14.7) 1
18 2.4 (2.2, 2.5) 10.2 (8.4, 12.3) 3 8.1 (6.5, 10.0) 3
31 3.8 (3.6, 4.0) 9.3 (7.9, 10.9) 4 6.3 (5.1, 7.6) 4
33 1.7 (1.6, 1.9) 13.2 (10.8, 16.0) 2 9.0 (7.0, 11.3) 2
a See Supplementary Tables for detailed breakdown of disease categories.
Editorial / Papillomavirus Research 2 (2016) 112–115 113studies indicate these two HPV genotypes have very different roles
in disease management. In particular while HPV 16 carries a
higher risk of CIN2 or greater (CIN2þ) at screening, but HPV18
does not. Its special role is more related to the fact that it is re-
latively more common in cancer and is also associated with ade-
nocarcinoma and CIN lesions in the endocervical canal (Table 2).
These lesions are less often detected by cytology and less visible on
colposcopy. Evidence for an increased risk of disease with HPV 18
is largely based on longitudinal follow up and is not seen cross-
sectionally [[8] and Refs. in Tables]. While HPV 16 positivity alone
may well be grounds for referral to colposcopy, HPV 18 positivity
alone will not be associated with higher CIN2þ detection rates.
Repeat HPV 18 positivity to establish persistence could potentially
be a better option in the absence of a cytologic abnormality. Fur-
ther the prevalence of HPV 18 in cancer does not automaticallyqualify it as a more important HPV genotype for screening pur-
poses, as many HPV18 related cancers are endocervical, and pre-
cursors are often not visible on colposcopy, so its detection may
not lead to cancer prevention.
Thus, clinically useful information is contained in a ﬁner clas-
siﬁcation of HPV genotypes [4] with one approach being to pro-
vide separate read outs for HPV 16, 18, 31, 33 and two pools – one
of ‘high risk’ types (HPV 35, 45, 51, 52, 58) and one of ‘intermediate
risk’ types ( HPV 39, 56, 59, 68). While this is not the only possible
extended genotyping approach, and these observations should not
lead to immediate changes in current screening recommendations,
it is clear that separate assessment of HPV 33 and 31 needs to be
reconsidered, as this is not possible with currently approved HPV
tests such as the Cobas test. Whether HPV 45 should be included
with HPV 18 is also an open question in need of further data. A
Table 2
Population prevalence of HPV 16, 18, 31, 33, 45 and relative risk with 95% conﬁdence intervals for A) squamous cancer (SCC), B) Adenocarcinoma (ADC, including ade-






Prevalence in squamous can-
cer % (95% CI)
Rel risk for squamous
cancer (95% CI)
Rank
IARC (world) [[21,22], Table 2; Table 2] N¼15, 613 normal,
9494 SCC
16 1.8 (1.6, 2.0) 55.2 (54.2, 56.2) 30.6 (27.2, 34.4) 1
18 .66 (0.54, 0.80) 12.8 (12.1, 13.5) 19.4 (15.9, 23.7) 2
31 .69 (0.56, 0.83) 3.8 (3.4, 4.2) 5.5 (4.4, 6.9) 5
33 .53 (0.42, 0.66) 3.7 (3.3, 4.1) 7.0 (5.5, 8.9) 4
45 .51 (0.41, 0.64) 4.6 (4.1, 5.2) 9.0 (7.0, 11.5) 3
New Mexico [[16], Table 2 and new data for SCC onlya]
N¼4007 controls, 660 SCC
16 7.4 (6.6, 8.3) 58.0 (54.2, 61.8) 7.8 (6.9, 8.9) 1
18 2.3 (1.8, 2.8) 9.8 (7.7, 12.4) 4.3 (3.2, 5.9) 3
31 2.9 (2.4, 3.5) 4.2 (2.8, 6.1) 1.4 (.97, 2.3) 6
33 .92 (0.65, 1.3) 4.8 (3.3, 6.8) 5.2 (3.3, 8.4) 2
45 2.2 (1.8, 2.8) 6.5 (4.6, 8.7) 2.9 (2.0, 4.1) 4
HPV35 5th
Denmark [[20], Tables 1 and 2] (N¼40 382, 19 SCC) 16 5.4 (5.1, 5.9) 57.9 (33.5, 79.7) 10.8 (7.3, 15.9) 1
18 2.4 (2.2, 2.5) 10.5 (13.0, 33.1) 4.4 (1.2, 16.4) 4
31 3.8 (3.6, 4.0) 5.3 (1.3, 26.0) 1.4 (0.21, 9.4) 5
33 1.7 (1.6, 1.9) 10.5 (13.0, 33.1) 6.1 (1.63, 22.5) 3
45 1.9 (1.8, 2.1) 15.8 (3.38, 39.6) 6.7 (2.3, 19.3) 2
B. Adenocarcinoma (including adenosquamous)
Study HPV type Population prevalence %
(95% CI)
Prevalence in adenocarcinoma %
(95% CI)
Rel risk for adenocarcinoma
(95% CI)
Rank
IARC (world) [[23], Table 2] N¼157 cases, 1609
controls
16 4.7 (3.7, 5.9) 42.7 (34.8, 50.8) 9.0 (6.8, 12.0) 3
18 1.2 (.71, 1.8) 31.8 (24.6, 39.7) 27.0 (16.3, 44.6) 1
31 0 (0.0, .2) 0 (0, 2.3) – –
33 .06 (.02, .35) .6 (.01, .35) 10.2 (.64, 163) 2
45 .68 (.34, 1.2) 3.8 (1.4, 8.1) 5.6 (2.1, 15.1) 4
New Mexico [[16], Table 2 and new data for ADC
onlya] N¼122 ADC, 4007 controls
16 7.4 (6.6, 8.3) 36.9 (28.3, 46.1) 5.0 (3.9, 6.4) 2
18 2.3 (1.8, 2.8) 28.9 (20.9, 37.6) 12.6 (8.9, 17.8) 1
31 2.9 ((2.4, 3.5) 3.3 (0.90, 8.2) 1.1 (.42, 3.0) 4
33 .92 (0.65, 1.3) 0 (0, 3.0) 0 –
45 2.2 (1.8, 2.8) .8 (.02, 4.5) 1.5 (.55, 3.9) 3
Denmark [[20], Tables 1 and 2] (N ¼40 382, 8 ADC) 16 5.4 (5.1, 5.9) 0 (0, 36.9) 0 –
18 2.4 (2.2, 2.5) 87.5 (47.3, 99.7) 36.8 (28.1, 48.1) 1
31 3.8 (3.6, 4.0) 12.5 (.32, 52.7) 3.3 (.53, 21.8) 2
33 1.7 (1.6, 1.9) 0 (0, 36.9) 0 –
45 1.9 (1.8, 2.1) 0 (0, 36.9) 0 –
C. Adenocarcinoma in Situ (AIS)
Study HPV type Population prevalence % (95%
CI)
Prevalence in AIS % (95% CI) Rel Risk for AIS (95% CI) Rank
New Mexico [[16], Table 2 and new dataa for AIS only]
N¼4007 controls, 25 AIS
16 7.4 (6.6, 8.3) 48.0 (27.8, 68.0) 6.5 (4.2, 9.9) 2
18 2.3 (1.8, 2.8) 48.0 (27.8, 68.0) 21.1 (13.4, 33.3) 1
31 2.9 (2.4, 3.5) 0 (0, 13.7) 0 –
33 .92 (.65, 1.3) 0 (0, 13.7) 0 –
45 2.2 (1.8, 2.8) 4.0 (0.10, 20.4) 1.8 (.26, 12.3) 3
Controls in Vaccine trials 15–26y [[18], Tables 1 and 3]
N¼17 590, 19 AIS
16 8.8 (8.4, 9.3) 78.9 (54.4, 93.9) 8.9 (7.1, 11.3) 2
18 3.6 (3.4, 3.9) 36.8 (16.3, 61.6) 10.7 (5.9, 19.1) 1
31 4.4 (4.1, 4.8) 0 (0, 17.6) 0 –
33 2.0 (1.8, 2.2) 5.3 (.13, 26.0) 2.5 (.38, 17.5) 3
45 2.4 (2.2, 2.6) 5.3 (.13, 26.0) 1.9 (0.29, 13.3) 4
Denmark [[20], Tables 1 and 2] (N¼40 382, 23 AIS) 16 5.4 (5.1, 5.9) 43.5 (23.2, 65.5) 8.1 (5.1, 12.9) 4
18 2.4 (2.2, 2.5) 60.9 (38.5, 80.3) 25.6 (18.3, 35.7) 1
31 3.8 (3.6, 4.0) 30.4 (13.2, 52.9) 8.1 (4.4, 15.0) 5
33 1.7 (1.6, 1.9) 21.7 (7.5, 43.7) 12.5 (5.7, 27.2) 2
45 1.9 (1.8, 2.1) 17.4 (5.0, 38.8) 8.9 (3.7, 21.9) 3
a See Supplementary Tables for detailed breakdown of disease categories.
Editorial / Papillomavirus Research 2 (2016) 112–115114ﬁner level of genotyping along with other discriminators not used
in current HPV testing algorithms such as viral load [5,9], methy-
lation status [10,11] and HPV variant status (esp for HPV 16 [12])
deserve further research to ﬁnd combinations that optimally use
sample information to stratify risk of high grade disease, both at
the time of screening and in the longer term, and to use thisinformation to improve management algorithms.
It is important to recognise that the aim of screening is to
prevent cancer and that the HPV distribution in cancers may not
accurately reﬂect the relative importance of different types in
doing this, as some cancers will not be detected by screening.
Cancer prevention is based on recognizing and treating precursor
Editorial / Papillomavirus Research 2 (2016) 112–115 115lesions before they become cancer. Doing this effectively and still
avoiding overtreatment should be the primary goal of a cervical
cancer screening programme.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.pvr.2016.05.004.References
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